Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

Pharmaceutical giant Novavax on Monday announced that the U.S. Food and Drug Administration (FDA) approved its COVID-19 ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) ...

The US Food and Drug Administration has fully approved a new COVID vaccine option specifically targeting high-risk individuals, including seniors. The protein-based Nuvaxovid vaccine, produced by ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...

US health regulators have given final approval to Novavax's COVID vaccine after an unusual delay and have placed new ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...